Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta
Introduction Osteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis medications but their effectiveness at preventing fractures is unknown. The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and...
Saved in:
Main Authors: | Jennifer Walsh, Catriona Keerie, Stuart H Ralston, Christopher J Weir, Muhammad K Javaid, WAYNE LAM, Bente L Langdahl, Jannie D Hald, Patricia Osborne |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/11/e078164.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
by: Tri Wahyu Martanto, et al.
Published: (2023-10-01) -
Osteogenesis Imperfecta, Pseudoachalasia, and Gastric Cancer
by: Dilsa Mizrak, et al.
Published: (2015-01-01) -
Genotype-Phenotype Correlations in Autosomal Dominant Osteogenesis Imperfecta
by: I. Mouna Ben Amor, et al.
Published: (2011-01-01) -
Osteogenesis Imperfecta (Type IV) with Dental Findings in Siblings
by: Shishir Ram Shetty, et al.
Published: (2011-01-01) -
Modern classification and molecular-genetic aspects of osteogenesis imperfecta
by: A. R. Zaripova, et al.
Published: (2020-04-01)